Kapitel 4: Hantering av MS-relaterade symtom - Neuroportalen
Kapitel 4: Hantering av MS-relaterade symtom - Neuroportalen
Kapitel 4: Hantering av MS-relaterade symtom - Neuroportalen
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
KAPITEL 4: HANTERING AV <strong>MS</strong>-RELATERADE SYMTOM<br />
EUROPEISKA <strong>MS</strong>-SJUKSKÖTERSKEMANUALEN<br />
Schmidt RT, Lee RH, Spehlmann R. Treatment of spasticity in multiple sclerosis:<br />
Comparison of dantrolene sodium and diazepam. Trans Am Neurol Assoc<br />
1975;100:235-237.<br />
Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of<br />
spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled<br />
trial. US Tizanidine Study Group. Neurology 1994;44(suppl 9):S34-S43.<br />
Smith PF, Darlington CL. Recent developments in drug therapy for multiple sclerosis.<br />
Mult Scler 1999;5:110-120.<br />
Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the<br />
treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse<br />
1987;7:39-50.<br />
United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of<br />
tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology<br />
1994;44(suppl 9):S70-S78.<br />
4?32